Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKDC | P78527 | 18/20 | 1.00 |
| ▸ | PIK3CA | P42336 | 4/20 | 1.00 |
| ▸ | MTOR | P42345 | 3/20 | 1.00 |
| ▸ | PIK3R1 | P27986 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 1.00 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.65 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | PDE2A | O00408 | 1/20 | 0.65 |
| ▸ | PIK3C2A | O00443 | 1/20 | 0.65 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.65 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.65 |
| ▸ | BRD4 | O60885 | 1/20 | 0.65 |
| ▸ | PDE5A | O76074 | 1/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.65 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.65 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.65 |
| ▸ | PIM1 | P11309 | 1/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30943704 | 1.00 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL29374897 | 1.00 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL30943705 | 1.00 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL31061492 | 0.96 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL3535232 | 0.89 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL3538224 | 0.88 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL3537126 | 0.85 | PRKDC (0.78) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL31060675 | 0.85 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL3538463 | 0.85 | PRKDC (0.78) | PRKDCPIK3CAMTORPIK3R1TDP1 | |
| SCHEMBL3537842 | 0.85 | PRKDC (1.00) | PRKDCPIK3CAMTORPIK3R1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024129605-A1 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRANT LEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-06-20 | — | — | WO | claimed |
| US-11833225-B2 | Methods and compositions for efficient gene deletion | CRISPR THERAPEUTICS AG (CH) | 2023-12-05 | — | — | US | claimed |
| US-20230181579-A1 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRAN TLEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | NATIONAL INSTITUTES OF HEALTH | 2023-06-15 | — | — | US | claimed |
| US-11672866-B2 | Osteotropic nanoparticles for prevention or treatment of bone metastases | UNM RAINFOREST INNOVATIONS | 2023-06-13 | — | — | US | claimed |
| WO-2023087022-A1 | METHODS AND COMPOSITIONS FOR GENOME EDITING | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-19 | — | — | WO | claimed |
| US-20220143035-A1 | METHODS FOR TREATING AUTOIMMUNE OR AUTOINFLAMMATORY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-12 | — | — | US | claimed |
| US-20210369725-A1 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRANT LEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | NATIONAL INSTITUTES OF HEALTH | 2021-12-02 | — | — | US | claimed |
| EP-3679144-A1 | METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF | Life Technologies Corporation (US) | 2020-07-15 | — | — | EP | claimed |
| WO-2019051316-A1 | METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF | Life Technologies Corporation (US) | 2019-03-14 | — | — | WO | claimed |
| US-20150366890-A1 | COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-24 | — | — | US | claimed |
| WO-2014130922-A1 | COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2014-08-28 | — | — | WO | claimed |
| US-20140113377-A1 | GENETIC MANIPULATION AND EXPRESSION SYSTEMS FOR PUCCINIOMYCOTINA AND USTILAGINOMYCOTINA SUBPHYLA | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2014-04-24 | — | — | US | claimed |
| EP-2718442-A1 | GENETIC MANIPULATION AND EXPRESSION SYSTEMS FOR PUCCINIOMYCOTINA AND USTILAGINOMYCOTINA SUBPHYLA | Temasek Life Sciences Laboratory Limited (SG) | 2014-04-16 | — | — | EP | claimed |
| WO-2013029116-A1 | METHOD FOR PREDICTING TREATMENT RESPONSIVENESS | MONASH UNIVERSITY (AU) | 2013-03-07 | — | — | WO | claimed |
| WO-2012169969-A1 | GENETIC MANIPULATION AND EXPRESSION SYSTEMS FOR PUCCINIOMYCOTINA AND US TILAGINOM YCOTINA SUBPHYLA | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2012-12-13 | — | — | WO | claimed |
| US-20100130597-A1 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICE (US) | 2010-05-27 | — | — | US | claimed |
| EP-2170338-A2 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (US) | 2010-04-07 | — | — | EP | claimed |
| US-20090035394-A1 | USE OF DNA-PK INHIBITION TO SENSITISE ATM DEFICIENT CANCERS TO DNA-DAMAGING CANCER THERAPIES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-02-05 | — | — | US | claimed |
| WO-2009008991-A2 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH (US) | 2009-01-15 | — | — | WO | claimed |
| US-12564589-B2 | Methods for treating cancer, reducing side effects of cancer treatment, and preventing the recurrence of cancer | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2026-03-03 | — | — | US | disclosed |
| EP-4662319-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | Integrate Bioscience LLC (US) | 2025-12-17 | — | — | EP | disclosed |
| US-20250288582-A1 | METHODS FOR TREATING CANCER, REDUCING SIDE EFFECTS OF CANCER TREATMENT, AND PREVENTING THE RECURRENCE OF CANCER | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2025-09-18 | — | — | US | disclosed |
| US-20250064821-A1 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRANT LEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2025-02-27 | — | — | US | disclosed |
| US-20240374764-A1 | COMBINATION RADIOTHERAPY | TELIX PHARMACEUTICALS (INNOVATIONS) PTY LTD. (AU) | 2024-11-14 | — | — | US | disclosed |
| WO-2024168301-A2 | PERSONALIZED CRISPR PROFILING FOR CANCER | FUNCTION ONCOLOGY, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| WO-2024129605-A1 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRANT LEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | FLORIDA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) | 2024-06-20 | — | — | WO | disclosed |
| CN-118119406-A | Combination radiation therapy | 泰利斯制药(创新)有限公司 | 2024-05-31 | — | — | CN | disclosed |
| US-11833225-B2 | Methods and compositions for efficient gene deletion | CRISPR THERAPEUTICS AG (CH) | 2023-12-05 | — | — | US | disclosed |
| US-20230323404-A1 | COMPOSITIONS AND METHODS FOR INCREASING HOMOLOGY-DIRECTED REPAIR | UNIV CALIFORNIA (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230183751-A1 | HDR ENHANCERS | OXFORD GENETICS LTD (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230183751-A1 | HDR ENHANCERS | OXFORD GENETICS LTD (GB) | 2023-06-15 | — | — | US | disclosed |
| US-20230181579-A1 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRAN TLEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | NATIONAL INSTITUTES OF HEALTH | 2023-06-15 | — | — | US | disclosed |
| US-11672866-B2 | Osteotropic nanoparticles for prevention or treatment of bone metastases | UNM RAINFOREST INNOVATIONS | 2023-06-13 | — | — | US | disclosed |
| WO-2023087022-A1 | METHODS AND COMPOSITIONS FOR GENOME EDITING | THE JOHNS HOPKINS UNIVERSITY (US) | 2023-05-19 | — | — | WO | disclosed |
| US-20220143035-A1 | METHODS FOR TREATING AUTOIMMUNE OR AUTOINFLAMMATORY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-12 | — | — | US | disclosed |
| US-20220143035-A1 | METHODS FOR TREATING AUTOIMMUNE OR AUTOINFLAMMATORY DISEASE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-05-12 | — | — | US | disclosed |
| US-20210369725-A1 | SELECTIVE TREATMENT OF CANCERS HAVING HISTONE H3 MUTATIONS OR ABERRANT LEVELS OF DNA OR HISTONE METHYLATION, ACETYLATION OR DEFECTS IN HOMOLOGOUS RECOMBINATION | NATIONAL INSTITUTES OF HEALTH | 2021-12-02 | — | — | US | disclosed |
| WO-2021234389-A1 | HDR ENHANCERS | Oxford Genetics Limited (GB) | 2021-11-25 | — | — | WO | disclosed |
| EP-3588089-B1 | CELL-BASED METHODS FOR COUPLING PROTEIN INTERACTIONS AND BINDING MOLECULE SELECTION AND DIVERSIFICATION | TECHNOPHAGE INVESTIG E DESENVOLVIMENTO EM BIOTECNOLOGIA SA (PT) | 2021-03-10 | — | — | EP | disclosed |
| EP-3679144-A1 | METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF | Life Technologies Corporation (US) | 2020-07-15 | — | — | EP | disclosed |
| EP-3679143-A1 | METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF | Life Technologies Corporation (US) | 2020-07-15 | — | — | EP | disclosed |
| US-20200101080-A1 | INHIBITORS OF DNA PK AND USES THEREOF | BIOVENTURES, LLC | 2020-04-02 | — | — | US | disclosed |
| US-10302653-B2 | Distinguishing antagonistic and agonistic anti B7-H1 antibodies | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2019-05-28 | — | — | US | disclosed |
| WO-2019051237-A1 | METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF | Life Technologies Corporation (US) | 2019-03-14 | — | — | WO | disclosed |
| WO-2019051316-A1 | METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOF | Life Technologies Corporation (US) | 2019-03-14 | — | — | WO | disclosed |
| EP-2718442-B1 | GENETIC MANIPULATION AND EXPRESSION SYSTEMS FOR PUCCINIOMYCOTINA AND USTILAGINOMYCOTINA SUBPHYLA | TEMASEK LIFE SCIENCES LABORATORY LTD (SG) | 2017-07-12 | — | — | EP | disclosed |
| EP-2718442-B1 | GENETIC MANIPULATION AND EXPRESSION SYSTEMS FOR PUCCINIOMYCOTINA AND USTILAGINOMYCOTINA SUBPHYLA | TEMASEK LIFE SCIENCES LABORATORY LTD (SG) | 2017-07-12 | — | — | EP | disclosed |
| US-9631196-B2 | Genetic manipulation and expression systems for Pucciniomycotina and Ustilaginomycotina subphyla | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2017-04-25 | — | — | US | disclosed |
| US-9631196-B2 | Genetic manipulation and expression systems for Pucciniomycotina and Ustilaginomycotina subphyla | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2017-04-25 | — | — | US | disclosed |
| US-20170089918-A1 | DISTINGUISHING ANTAGONISTIC AND AGONISTIC ANTI B7-H1 ANTIBODIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2017-03-30 | — | — | US | disclosed |
| US-20170056336-A1 | CO-TARGETING ANDROGEN RECEPTOR SPLICE VARIANTS AND MTOR SIGNALING PATHWAY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-03-02 | — | — | US | disclosed |
| US-9511086-B2 | Method for improving immune system function by administering agents that inhibit DNA-dependent protein kinase-directed apoptosis | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2016-12-06 | — | — | US | disclosed |
| US-9487773-B2 | Cell-based methods for coupling protein interactions and binding molecule selection | TECHNOPHAGE, INVESTIGACAO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA (PT) | 2016-11-08 | — | — | US | disclosed |
| EP-2962103-A2 | CELL-BASED METHODS FOR COUPLING PROTEIN INTERACTIONS AND BINDING MOLECULE SELECTION AND DIVERSIFICATION | Technophage, Investigação E Desenvolvimento Em Biotecnologia, SA (PT) | 2016-01-06 | — | — | EP | disclosed |
| US-20150366890-A1 | COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-12-24 | — | — | US | disclosed |
| WO-2015179654-A1 | DISTINGUISHING ANTAGONISTIC AND AGONISTIC ANTI B7-H1 ANTIBODIES | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2015-11-26 | — | — | WO | disclosed |
| WO-2014133405-A2 | CELL-BASED METHODS FOR COUPLING PROTEIN INTERACTIONS AND BINDING MOLECULE SELECTION AND DIVERSIFICATION | TECHNOPHAGE, INVESTIGAÇÃO E DESENVOLVIMENTO EM BIOTECNOLOGIA, SA (PT) | 2014-09-04 | — | — | WO | disclosed |
| US-20140249044-A1 | Cell-Based Methods for Coupling Protein Interactions and Binding Molecule Selection and Diversification | Technophage, Investigaçâo E Desenvolvimento Em Biotecnologia, SA (PT) | 2014-09-04 | — | — | US | disclosed |
| WO-2014130922-A1 | COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS | TRUSTEES OF BOSTON UNIVERSITY (US) | 2014-08-28 | — | — | WO | disclosed |
| US-20140113377-A1 | GENETIC MANIPULATION AND EXPRESSION SYSTEMS FOR PUCCINIOMYCOTINA AND USTILAGINOMYCOTINA SUBPHYLA | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2014-04-24 | — | — | US | disclosed |
| US-20140113377-A1 | GENETIC MANIPULATION AND EXPRESSION SYSTEMS FOR PUCCINIOMYCOTINA AND USTILAGINOMYCOTINA SUBPHYLA | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2014-04-24 | — | — | US | disclosed |
| EP-2718442-A1 | GENETIC MANIPULATION AND EXPRESSION SYSTEMS FOR PUCCINIOMYCOTINA AND USTILAGINOMYCOTINA SUBPHYLA | Temasek Life Sciences Laboratory Limited (SG) | 2014-04-16 | — | — | EP | disclosed |
| US-20130177921-A1 | Detection of Damage to DNA | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2013-07-11 | — | — | US | disclosed |
| US-20130109687-A1 | METHODS OF TREATING HIV INFECTION: INHIBITION OF DNA DEPENDENT PROTEIN KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2013-05-02 | — | — | US | disclosed |
| US-20130109687-A1 | METHODS OF TREATING HIV INFECTION: INHIBITION OF DNA DEPENDENT PROTEIN KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2013-05-02 | — | — | US | disclosed |
| WO-2012169969-A1 | GENETIC MANIPULATION AND EXPRESSION SYSTEMS FOR PUCCINIOMYCOTINA AND US TILAGINOM YCOTINA SUBPHYLA | TEMASEK LIFE SCIENCES LABORATORY LIMITED (SG) | 2012-12-13 | — | — | WO | disclosed |
| US-20120289432-A1 | PI3K MODULATORS, RHO KINASE MODULATORS AND METHODS OF IDENTIFYING AND USING SAME | CORNING INCORPORATED (US) | 2012-11-15 | — | — | US | disclosed |
| US-20120039867-A1 | Immune System Function in Conditions Characterized by Elevated Double Strand Breaks | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-02-16 | — | — | US | disclosed |
| WO-2011137428-A1 | METHODS OF TREATING HIV INFECTION: INHIBITION OF DNA DEPENDENT PROTEIN KINASE | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-11-03 | — | — | WO | disclosed |
| US-20100130597-A1 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICE (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130597-A1 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICE (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100130597-A1 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | THE UNITED STATE OF AMERICA, AS REPRESENTED BY THE SECRETARY OF THE DEPT OF HEALTH AND HUMAN SERVICE (US) | 2010-05-27 | — | — | US | disclosed |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-04-15 | — | — | US | disclosed |
| EP-2170338-A2 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20100062437-A1 | PARALLEL PROFILLING OF SIGNALING PATHWAYS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY | 2010-03-11 | — | — | US | disclosed |
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-7674823-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2010-03-09 | — | — | US | disclosed |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | COMBINATORX (SINGAPORE) PTE. LTD. (SG) | 2010-01-14 | — | — | US | disclosed |
| US-20090035394-A1 | USE OF DNA-PK INHIBITION TO SENSITISE ATM DEFICIENT CANCERS TO DNA-DAMAGING CANCER THERAPIES | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-02-05 | — | — | US | disclosed |
| WO-2009008991-A2 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2009008991-A2 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | EXCRX (SINGAPORE) PTE. LTD. (F.K.A. COMBINATORX (SINGAPORE) PTE LTD.) (SG) | 2008-07-03 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-20070238729-A1 | DNA-PK INHIBITORS | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-10-11 | — | — | US | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-7226918-B2 | DNA-PK inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2007-06-05 | — | — | US | disclosed |
| US-20040192687-A1 | Dna-pk inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
| US-20040192687-A1 | Dna-pk inhibitors | CANCER RESEARCH CAMPAIGN TECHNOLOGY LIMITED (GB) | 2004-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220143035-A1 | METHODS FOR TREATING AUTOIMMUNE OR AUTOINFLAMMATORY DISEASE | HSPA8, HSPBP1, HSP90AB1 | PRKDC 19/4885PIK3CA 1744/4885MTOR 646/4885 |
| US-12564589-B2 | Methods for treating cancer, reducing side effects of cancer treatment, and preventing the recurrence of cancer | BRCA1, PARP1, PARP2 | PRKDC 37/4885PIK3CA 215/4885MTOR 728/4885 |
| US-20100130597-A1 | DNA-PKCS MODULATES ENERGY REGULATION AND BRAIN FUNCTION | PRKAB1, PRKAG1, PRKAB2 | PRKDC 81/4885PIK3CA 564/4885MTOR 936/4885 |
| US-20100009970-A1 | COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL DISEASES | HTR1A, HTR3B, HTR3A | PRKDC 2562/4885PIK3CA 2678/4885MTOR 526/4885 |
| US-11672866-B2 | Osteotropic nanoparticles for prevention or treatment of bone metastases | SOST, ACP3, KLK3 | PRKDC 3501/4885PIK3CA 48/4885MTOR 1229/4885 |
| US-20130109687-A1 | METHODS OF TREATING HIV INFECTION: INHIBITION OF DNA DEPENDENT PROTEIN KINASE | DCK, POLK, VRK1 | PRKDC 36/4885PIK3CA 504/4885MTOR 450/4885 |
| US-20040192687-A1 | Dna-pk inhibitors | ATM, CHEK1, XRCC6 | PRKDC 92/4885PIK3CA 250/4885MTOR 803/4885 |
| US-20080161324-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, EIF2AK2, RNASE1 | PRKDC 3363/4885PIK3CA 1304/4885MTOR 1929/4885 |
| US-20070238729-A1 | DNA-PK INHIBITORS | ATM, CHEK2, CHEK1 | PRKDC 212/4885PIK3CA 219/4885MTOR 620/4885 |
| US-20100092479-A1 | Compositions and methods for treatment of viral diseases | HAVCR2, RNASE1, EIF2AK2 | PRKDC 2817/4885PIK3CA 1237/4885MTOR 3277/4885 |
| US-20090035394-A1 | USE OF DNA-PK INHIBITION TO SENSITISE ATM DEFICIENT CANCERS TO DNA-DAMAGING CANCER THERAPIES | ATM, CHEK2, DCK | PRKDC 37/4885PIK3CA 554/4885MTOR 841/4885 |
| US-20150366890-A1 | COMPOSITIONS AND METHODS FOR TREATING FUNGAL INFECTIONS | ERG28, DPM1, COXFA4L2 | PRKDC 34/4885PIK3CA 1898/4885MTOR 788/4885 |
| US-20170056336-A1 | CO-TARGETING ANDROGEN RECEPTOR SPLICE VARIANTS AND MTOR SIGNALING PATHWAY FOR THE TREATMENT OF CASTRATION-RESISTANT PROSTATE CANCER | AR, MTOR, RICTOR | PRKDC 3250/4885PIK3CA 104/4885MTOR 2/4885 |
| US-20200101080-A1 | INHIBITORS OF DNA PK AND USES THEREOF | DTYMK, DCLRE1B, UNG | PRKDC 72/4885PIK3CA 701/4885MTOR 2659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.